Wait, don't miss out on the latest GovCon industry news!

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings

*By clicking "Join us now" you agree to receive email, promotions and general messages from GovCon Wire, In addition, you also agree to GovCon Wire Privacy Policy and Terms & Conditions.

X Remind me Later

FDA Selects Four Firms to Develop Automated Biological Product Reporting Methods

The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.

IBM (NYSE: IBM), Acumen, Dovel Technologies and IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.

FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.

The indefinite delivery/indefinite quantity contracts have a five-year ordering period.

The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles